immatics biotechnologies closes Series D
immatics biotechnologies has closed a Series D financing round. The funding round was supported by existing investors including dievini Hopp Biotech holding, Wellington Partners, MIG-advised funds and AT Impf GmbH. immatics biotechnologies is a clinical-stage biopharmaceutical company developing advanced multi-peptide cancer vaccines that are active against cancer.
15 October 2013•4 mins read
